European Commission Approves AQUIPTA® (atogepant) for Acute Migraine Treatment in Adults

The European Commission has granted approval for AQUIPTA® (atogepant) for the acute treatment of migraine in adults, with or without aura, and as a once-daily preventive treatment for adults experiencing four or more migraine days per month. This regulatory action, based on positive Phase 3 clinical trial data, expands treatment options for adult migraine patients in the European Union, offering fast and lasting relief.